Breaking News

Emergex T-Cell Priming COVID Vax Candidate Holds Potential Against Omicron

Phase I vaccine candidate has the potential to be effective against all currently known variants and would eliminate the need for seasonal booster.

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Emergex Vaccines Holding Ltd., a company tackling major global infectious disease threats through the development of 100% synthetic T-Cell priming vaccines, confirmed that its vaccine candidate for SARS-CoV-2, the virus which causes COVID-19, has the potential to be effective against all currently known variants.   Emergex has initiated a Phase I trial of the vaccine candidate at the Center for Primary Care and Public Health at the University of Lausanne, Switzerland.   Professor Thomas Rade...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters